Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140597 | 0.91 | TRPV4 (0.52) | SRD5A2MRGPRX4VNN1HDAC4TRPV4 | |
| SCHEMBL14033189 | 0.85 | VNN1 (0.48) | SRD5A2HPGDVNN1TRPV4CA1 | |
| SCHEMBL29418677 | 0.82 | L3MBTL1 (0.57) | SRD5A2ALDH1A1MRGPRX4HPGDHSD17B10 | |
| SCHEMBL186213 | 0.82 | L3MBTL1 (0.57) | SRD5A2ALDH1A1MRGPRX4HPGDHSD17B10 | |
| SCHEMBL15647834 | 0.82 | GRM5 (0.52) | SRD5A2MRGPRX4VNN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21767713 | 0.80 | L3MBTL1 (0.56) | SRD5A2ALDH1A1MRGPRX4HPGDHSD17B10 | |
| SCHEMBL15774236 | 0.78 | TRPV4 (0.50) | MRGPRX4HDAC4TRPV4CNR2 | |
| SCHEMBL4504526 | 0.78 | NPC1 (0.65) | ALDH1A1KDM4ERAB9A | |
| SCHEMBL5042391 | 0.77 | ALDH1A1 (0.54) | SRD5A2ALDH1A1HPGDVNN1HTT | |
| SCHEMBL934659 | 0.77 | TRPV4 (0.48) | MRGPRX4HDAC4TRPV4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| WO-2015153381-A2 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-08 | — | — | WO | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | SRD5A2 1954/4885ALDH1A1 149/4885MRGPRX4 3582/4885 |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | PPOX, DDC, DDO | SRD5A2 1943/4885ALDH1A1 130/4885MRGPRX4 3219/4885 |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | SRD5A2 1954/4885ALDH1A1 149/4885MRGPRX4 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.